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Alzheimer’s disease (AD) is an aging-related 
progressive neurodegenerative disease, characterized by 
massive neuronal and synaptic loss, accompanied by 
neuropathological changes, such as neurofibrillary 
tangles and senile plaques, in the hippocampus, 
neocortex, and subcortical structures [1]. The senile 
plaques are primarily composed of amyloid beta peptide 
(Aβ), which is a 40–42 amino acid peptide fragment of 
the amyloid protein precursor. However, the mechanism 
by which Aβ causes neuronal injury and cognitive 
impairment is unclear. AD is also thought to have a 
local, non-immune mediated neuroinflammatory com-
ponent with clusters of  activated  microglia,   increased 
 
 








































































inflammatory proteins  (complement factors, acute-
phase protein, pro-inflammatory cytokines) [2-4], and 
increased COX-1-expressing microglia surrounding 
amyloid plaques [2]. Changes in COX-2 expression in 
AD are discrepant and seem to depend on the stage of 
the disease, with an upregulation of COX-2 in early 
AD, and a downregulation in advanced AD stages, 
which also correlate with PGE2 levels in the CSF, which 
are increased in probable AD patients and decrease with 
the progression of the disease [5, 6]. Several 
independent epidemiological studies have shown that 
early use of non steroidal anti-inflammatory drugs 
(NSAIDs), which inhibit COX activity, significantly 
reduces the risk of developing AD later in life 
suggesting that inflammation is critical for the 
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6-month, double-blinded, placebo-controlled study with 
indomethacin, a preferential COX-1 inhibitor, appeared 
to protect AD patients from cognitive decline [14], 
subsequent large-scale randomized clinical trials, 
mostly with selective COX-2 inhibitors, did not show 
any beneficial effects in AD patients with mild to severe 
symptoms [15-18]. Supporting these clinical data, 
indomethacin, but not the COX-2 selective nimesulide, 
significantly reduced levels of Aβ in the hippocampus 
and cortex of transgenic mouse models of AD [19]. 
While the clinical data seem to rule out a protective 
effect of selective COX-2 inhibition in AD, it is still 
unclear whether COX-2 inhibitors can improve the 
pathology in animal models of AD. For instance, COX-
2 inhibition blocks Aβ-mediated suppression of long-
term potentiation and memory function, independently 
of reductions in Aβ1-42  or in inflammation [20]. 
However, the selective COX-2 inhibitor celecoxib has 
been shown to increase Aβ levels [21, 22], and in a 
model of acute inflammation, both genetic deletion and 
pharmacological inhibition of COX-2 worsen the 
neuroinflammatory response to lipopolysaccharide 
(LPS) [23]. These combined data suggest that either 
NSAIDs have rather a preventive than a therapeutic 
effect or that preferential COX-1 inhibition is a better 
therapeutic approach than selective targeting COX-2, or 
that the beneficial effects are due to COX-independent 
effects of NSAIDs. In particular, ibuprofen, 
flurbiprofen, and diclofenac have been shown to reduce 
serum Aβ1-42 levels, a major component of senile 
plaques in AD [24-28]. However, a recent report from a 
pooled dataset from six prospective studies indicated 
that NSAIDs use reduced the risk of AD without any 
apparent advantage for the subset of NSAIDs shown to 
selectively lowering Aβ1-42 [29]. While COX-1 and 
COX-2 are both differentially expressed in different 
stages of AD pathology, their specific roles in the 
pathogenesis of AD is unclear. Therefore, a full 
understanding of the physiological, pathological, and/or 
neuroprotective role of COX isoforms may help to 
develop better therapeutic strategies for the prevention 
or treatment of AD. 
 
Partial reproduction of AD neuropathology and 
cognitive deficits has been achieved with pharma-
cological and genetic approaches. Most injection 
models use synthetic peptide Aβ1-40 or Aβ1-42, which are 
analogous to peptides found in neuritic plaques in AD 
patients [30]. Mice with a null mutation of COX gene 
have been a useful tool for investigating the role of each 
COX isoform in both physiological and pathological 
conditions in the CNS by overcoming the complexity of 
dosing paradigm, duration of treatment, and possible 
unspecific inhibition of both COX isoform [31]. In this 
study, we assessed the effect of intracerebroventricular 
(i.c.v.) injection of Aβ1-42 on acute neuroinflammatory 
response in COX-1-deficient (COX-1
-/-) mice and their 
respective wild-type mice (WT) controls. We showed 
that COX-1
-/- mice are more resistant than WT mice to 
Aβ1-42-induced neuronal death and exhibit a marked 




The inflammatory response is reduced in COX-1
-/- 
mice after Aβ1-42 injection 
 
Aβ1-42 or the control reverse peptide Aβ42-1 was 
unilaterally injected into the lateral ventricle, as 
reported [32-35]. Seven days later, brains were removed 
and coronal sections were processed for 
immunohistochemistry. We assessed microglial 
activation in the brain using IBA-1 as a microglial 
marker. Aβ1-42 administration caused a robust 
inflammatory response within the CA1 and CA3 areas 
of the hippocampus of WT mice characterized primarily 
by the presence of activated microglia (Figure 1A, D, J). 
Intense IBA-1-immunoreactive microglia with 
enhanced staining intensity, retracted processes, 
perikaryal hypertrophy, and amoeboid appearance were 
observed in the CA3 area of hippocampus of WT mice 
(Figure 1G). In COX-1
-/- mice, IBA-1-immunreactive 
microglia retained a resting morphology with 
specifically small cell bodies, thin, and ramified 
processes (Figure 1B, E, H, J). In reverse peptide Aβ42-
1-injected mice, only a few faintly IBA-1-
immunoreactive microglia were observed in the 
hippocampus (Figure 1C, F, I, J). Staining with CD11b, 
another marker for microglia gave results similar to that 
of IBA-1 (data not shown). 
 
We then assessed astrocytes immunoreactivity by 
staining the brain of WT and COX-1
-/- mice with the 
astrocytic marker glial fibrillary acidic protein (GFAP). 
GFAP-immunoreactive astrocytes in response to Aβ1-42 
injection were markedly attenuated in the brain of COX-
1
-/- mice (Figure 2B, E, H) compared to WT mice 
(Figure A, D, G). These results indicate that Aβ1-42 
administration induced less severe glial cell activation 
in COX-1
-/- mice compared to WT mice. 
 
COX-1 deficiency leads to reduced neuronal damage 
following Aβ1-42 injection 
 
We next assessed neuronal damage in the brain using 
the fluorescent marker Fluoro-Jade B (FJB), which 
selectively labels injured neurons [36, 37]. Aβ1-42 
administration caused a significant neuronal damage, 
characterized by the presence of FJB-positive neurons  
   
















































within the CA3 areas of hippocampus of WT mice 
(Figure 3A, J). In contrast, Aβ1-42-injected  COX-1
-/- 
mice showed few scattered FJB-positive neurons in the 
CA3 of hippocampus (Figure 3B, J). In same sections 
stained with DAPI or adjacent sections stained with 
cresyl violet, a similar distribution of neuronal loss and 


























































Aβ1-42-injected WT mice (Figure 3D, G). FJB and Nissl 
staining showed that hippocampal CA3 neurons in 
COX-1
-/- mice were better preserved than in WT mice 
(Figure 3E, H). These results indicate that Aβ1-42 
administration induced less severe neuronal damage in 
COX-1
-/- mice compared to WT mice. 
 
   





























-/- mice exhibit reduced oxidative damage 
following Aβ1-42 administration 
 
An important component of Aβ1-42-induced neurotoxic 
process is mediated by oxidative damage [38], which 
can be evaluated by assessing protein carbonyls and 
nitrotyrosine levels [39]. To determine whether 
oxidative damage is involved in the process of Aβ1-42-
induced neurotoxic process, we investigated oxidized 
amino acid, nitrotyrosine levels using sections adjacent 
to those used for FJB staining. We found an increase in 
nitrotyrosine-immunoreactive cells in the brain of WT 
mice (Figure 4A, D), which was markedly attenuated in  
the brain of COX-1
-/- mice (Figure 4B, E). These results 
indicate that Aβ1-42 administration induced less severe 
oxidative damage in COX-1
-/- mice compared to WT 
mice. 
 




To determine the contribution of COX-1 to PG 
production after Aβ1-42 injection, we measured the 
levels of PGE2, PGF2α, and TXB2 24 h after Aβ1-42 
administration. We observed significant reduction in 
levels of PGE2 (Figure 5A), PGF2α (Figure 5B), and 
TXB2 (Figure 5C) in Aβ1-42-injected COX-1

































These results suggest that the reduced levels of PGE2, 
PGF2α, and TXB2 in COX-1
-/- mice could contribute, in 
part, to the observed differences in glial and neuronal 




In this study, genetic deletion of COX-1 led to a 
decrease in the inflammatory response and neuronal 
damage in response to Aβ1-42, and this effect was 
associated with alteration of PG production. We show 
that Aβ1-42-induced oxidative damage and degenerating 
neurons, as well as glial activation, were less severe in 
COX-1
-/- mice compared to WT mice. These data 
suggest that COX-1 facilitates activation of glial cells 
and supports inflammatory processes and oxidative 
stress that evolve in neuronal damage, and support 
previous data from our lab showing that COX-1
-/- mice 
have a decreased inflammatory response, oxidative 
stress and neuronal damage after central injection of 
LPS [37]. 
 
Glial cell activation, in turn, results in enhanced 
production of a variety of proinflammatory and 
oxidative mediators, including cytokines, chemokines, 
and reactive oxygen/nitrogen species [40-42]. Oxidative 
stress has been recognized to play an important role in 
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by the finding of several characteristics, such as enhanced 
protein, DNA oxidation, and lipid peroxidation in 
specific regions of the postmortem brain [43-48]. A 
previous study suggested that oxidative DNA damage 
reduces the expression of highly vulnerable genes 
involved in neuronal survival and learning memory, 
initiating a program of brain aging that starts early in 
adult life [49]. In addition, lipid peroxidation leads to a 
reduction in membrane fluidity, alteration of membrane-
bounded protein, receptors, and ion channels, and 
generation of Aβ that induces more oxidative stress and 
calcium influx that induces glutamate excitotoxicity and 
cell death [50, 51]. The abundant polyunsaturated lipid 
content, high oxygen consumption, high metal ion 







































relatively low antioxidant levels compared with other 
tissues make brain highly susceptible to oxidative 
damage [49, 52]. In addition, oxidative stress 
differentially affects brain regions, as levels of peroxi-
dizable unsaturated lipids and antioxidant enzymes, and 
membrane-bound protein differ between brain regions. In 
this regard, continuous icv infusion of Aβ1-42 results in a 
significant reduction of endogenous antioxidant systems, 
including Mn-superoxide dismutase (Mn-SOD), 
glutathione, glutathione peroxidase, and glutathione-S-
transferase-π in the hippocampus, cortex, substantia 
nigra, and thalamus [53]. Importantly, these alterations of 
each antioxidant enzyme were not uniform, but rather 
specific in a brain region-dependent manner (e.g. Mn-
SOD in CA3), indicating a heterogenous susceptibility to 






































Figure  3. Increased  degenerating  neurons  in  the
hippocampus 7 d after Aβ1‐42 administration. (A‐C)
















   
www.impactaging.com                  238                                AGING, February 2009, Vol.1 No.2Our results show that a single injection of Aβ1-42 
resulted in a similar spatial distribution of reactive glial 
cells, nitrotyrosine, and degenerating neurons in the 
CA3 of hippocampus, suggesting the possibility that 
glial cell-derived reactive oxygen/nitrogen species may 
be involved in the impaired neuronal function, which 
has been described in this model [32, 33, 54, 55]. 
Indeed, several studies have shown that pretreatment 
with antioxidants or minocycline, a tetracycline 
derivative with anti-inflammatory and neuroprotective 
properties, tend to ameliorate the Aβ1-42-induced 
oxidative damage and behavioral deficits [32,33,56]. 
Although, variable in terms of the injected Aβ peptide 
sequences, injection methods, and employed behavioral 
tests, previous studies have consistently shown the 
occurrence of behavioral deficits related to memory 
impairment after intracerebral injection of Aβ peptide 
[32, 33, 57-59]. Therefore, Aβ injection is a useful in 
vivo model for Aβ toxicity, which is an important 
component in the progression of AD.  
 
Gene deletion of COX-1 decreased glial cell activation 
































oxidative damage in COX-1
-/- mice suggests that COX-1 
deletion can reduce the activity of free-radical generating 
enzymes such as inducible nitric oxide (iNOS), NADPH 
oxidase, and myeloperoxidase (MPO). These data are 
consistent with recent observations that genetic deletion 
of COX-1 significantly reduces LPS-induced expression 
of both superoxide (O2
-) and NO-forming enzymes and 
thus subsequently attenuates the levels of nitrotyrosine 
and protein carbonyls, which are considered as 
biomarkers of oxidative stress [37]. Although, the precise 
mechanism(s) by which COX-1 regulates free radical-
generating enzymes in inflammatory cascade have not 
been clearly established, it is possible that because of its 
predominant localization in microglia, COX-1 can 
modulate the induction of O2
-, as well as NO, from 
NADPH oxidase and iNOS, which, in turn, can enhance 
the production of more potent free radicals such as 
peroxynitrite (ONOO
-). In addition, O2
- and NO act as 
potent cell signaling molecules and amplify production of 
TNF-α and PGE2 by upregulation of COX-2 [60]. These 
initial effects combined with the activation of seconddary 
signaling cascades activate a robust immune response 






































   








































The results from epidemiological data indicating that 
NSAIDs are effective in preventing or delaying the 
onset of AD combined with the failure of COX-2 
selective inhibitors in clinical trials in AD patients with 
moderate to severe AD suggest that either an early 
treatment is crucial to stop the mechanisms underlying 
the disease before the onset of the symptoms or that 
COX-2 selective inhibitors are not effective in delaying 
the progression of AD. In this regard, an intriguing 
hypothesis is that the protective effects of NSAIDs may 
be related to COX-1 rather than COX-2 inhibition. 
Supporting this hypothesis, COX-1 selective inhibitors 
(SC-560 and valeryl salicylate), but not COX-2 
selective inhibitors (SC-236 and DuP-697), reduce Aβ1-
42-induced PGs production and neurotoxicity in 
postmortem human microglia and in murine cortical 
neurons [61, 62]. Furthermore, a small double blind, 
placebo-controlled study with indomethacin, a preferen-
tial COX-1 inhibitor [63], appeared to protect mild to 
moderately impaired AD patients from cognitive 
decline [14]. Interestingly, COX-1 is prominently 
expressed by microglia in rodent and human brain [2, 4] 
and appears to be increased in AD brain [2]. Double 
immunostaining for Aβ and COX-1 indicates clustering 
of COX-1 positive microglia with classicaland neuritic 
plaques, although there is no indication that COX-1 is 
upregulated in activated microglia [64]. However, LPS-
induced PGE2 secretion can be reduced by COX-1 
genetic deletion and by COX-1 selective inhibitors [37, 
61, 65], suggesting that it is dependent on the 
constitutive COX-1 activity. In contrast, COX-2 has not 
been detected in microglia and astrocytes in AD [66]. 
These combined data suggest that COX-2 may not be 
the exclusive COX isoform responsible for patho-
physiological consequences in neurodegenerative 
diseases, especially in AD, but that COX-1 also plays a 
critical role in the process of neuroinflammation and 
neurodegeneration.  
 
In summary, we show that COX-1 facilitates activation 
of glial cells and supports inflammatory processes and 
that genetic deletion of COX-1 significantly attenuates 
the oxidative stress and neuronal damage in response to 
Aβ1-42. This effect may be due to the predominant 
localization of COX-1 in microglial cells, where, 
through its prostaglandin products contributes to the 
neuroinflammatory cascade of events that ultimately 
lead to neuronal damage or death. Therefore, COX-1 
may represent a viable therapeutic target to treat 












MATERIALS AND METHODS 
 
Animals and stereotaxic Aβ1-42 administration. Three-
month-old male homozygous COX-1
-/- and their WT 
mice (COX-1
+/+) on a C57BL/6-129/Ola genetic 
background were used [67]. Mice were received at our 
animal facility at 6 weeks of age from a NIEHS colony 
maintained by Taconic Farms (Germantown, NY) with 
heterozygous by heterozygous breedings for greater 
than 35 generations. In order to prevent the inclusion of 
strain or genetic background confounders between COX 
null and wild type mice, all of the mice used in this 
study were progeny derived from heterozygous by 
heterozygous mating and therefore all contained the 
same strain and genetic background [67, 68]. The mice 
were housed
 at 25°C in our animal facility with a 12 h 
light/dark cycle
 with free access to food and water. All 
animal procedures were approved by the National 
Institutes of Health (NIH) Animal Care and Use 
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care and use of laboratory animals. Aβ1-42  and reverse 
peptide Aβ42-1 (American Peptide, Sunnyvale, CA) were 
reconstituted in phosphate-buffered saline (pH 7.4) and 
aggregated by incubation at 37°C for 4 days before use as 
described previously [69]. Aβ1-42 and Aβ42-1 (400 pmol 
per mouse) were administered intracerebroventricularly 
(i.c.v) into the lateral ventricle using a 10 μl syringe with 
a fine needle (World Precision Instruments, Sarasota, FL) 
and a syringe pump (Stoelting, Wood Dale, IL) at a rate 
of 1 µl/min. The dose of Aβ1-42 and Aβ42-1 was selected 
based on previous studies [32-35].
 The coordinates for 
the stereotaxic injections were –2.3
 mm dorsal/ventral, –
1.0 mm lateral, and –0.5 mm
 anterior/posterior from the 
bregma [70]. 
 
Tissue preparation and histology.  Mice were 
transcardially perfused with
  saline followed by 4% 
paraformaldehyde. Brains were postfixed
  overnight in 
the same medium and placed in 30% sucrose, before 
sectioning (30 µm). Immunohistochemistry and double 
immunofluorescence were performed as described 
previously [71]. Rabbit anti-IBA-1 (1:500; Wako), 
mouse anti-GFAP (1:200; Sigma-Aldrich), and mouse 
anti-nitrotyrosine (1:100; Chemicon, Temecula, CA) 
were used as primary antibodies. The slides were 
visualized by brightfield microscopy (Olympus) and 
digitally photographed. FJB, a fluorochrome for the 
sensitive histochemical
  localization of neuronal 
degeneration, was used to identify
 degenerating neurons 
[72]. Brain
  sections were mounted on gelatin-coated 
slides and completely
  dried. Then sections were 
rehydrated through graded concentrations
  of alcohol 
(100, 70, and 50%; 1 min each), and rinsed for 1
 min in 
distillated water. The slides were incubated in a solution 
of 0.06%
 potassium permanganate for 20 min, rinsed
 in 
distilled water for 1 min, and transferred to FJB 
(Histochem, Jefferson, AR) staining
  solution (0.001% 
FJB/0.1% acetic acid) for 20 min. The slides were 
thereafter rinsed three times in distilled water and air 
dried then immersed
  in xylene and coverslipped with 
mounting media. The slides were visualized by 
fluorescent microscopy (Olympus) and digitally 
photographed. Because the FJB staining was obvious on 
digital imaging, the number of FJB-positive cells per 
section was quantified as described previously [73]. The 
number of microglia per section was quantified by 
counting the number of IBA-1-stained cell bodies 
within 0.3 mm
2 area of the CA3. For each measurement, 
two blinded independent investigators counted 3-4 
brains per group, 3 sections per brain. 
 
Measurement of prostanoids. Prostanoids were purified 
from the lipid extract as previously described [74] and 
levels were determined using specific enzyme 
immunoassay (EIA) kits, PGE2, PGF2α, and TXB2, 
(Oxford Biomedical, Oxford, MI). 
 
Statistics.  All data are expressed as mean ± SEM. 
Statistical significance was assessed with one-way 
analysis of variance (ANOVA) followed by 
Bonferroni’s post hoc test using GraphPad Prism 
version 4.00 (GraphPad Software, San Diego, CA). 
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